Collegium Pharmaceutical, Inc. announced its full-year 2025 financial guidance, projecting net product revenues in the range of $735 million to $750 million. This guidance reflects expected significant top- and bottom-line growth for the company. The company's strategy includes commercial expansion for Jornay PM and maximizing its pain portfolio.
Jornay PM net revenue is expected to be in excess of $135 million for 2025, positioning it as the lead growth driver. Adjusted EBITDA is anticipated to be in the range of $435 million to $450 million, with adjusted operating expenses expected between $220 million and $230 million. These projections are driven by the addition of Jornay PM and continued performance from the pain portfolio.
Collegium plans to make targeted investments in Jornay PM throughout 2025 to accelerate its growth in the near-term and create momentum for 2026 and beyond. The company also stated its commitment to strategically deploying capital in a disciplined manner to create long-term value for shareholders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.